NEVADA CANCER INST has a total of 17 patent applications. Its first patent ever was published in 2006. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are JACKSON LAB, ALTERNATIVE GENE EXPRESSION S L ALGENEX and GENCOM CO.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 4 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Canada | 2 | |
#5 | China | 1 | |
#6 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Agriculture | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Analysing materials | |
#4 | Animal care | |
#5 | Therapeutic chemical compounds | |
#6 | Medical preparations | |
#7 | Measuring microorganism processes | |
#8 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Ma Yupo | 10 |
#2 | Pizzorno Giuseppe | 3 |
#3 | Fink Louis M | 2 |
#4 | Ward David C | 2 |
#5 | Ye Tao | 1 |
#6 | Quan Junmin | 1 |
#7 | Xu Dan | 1 |
#8 | Xu C Wilson | 1 |
#9 | Waner Milton | 1 |
#10 | Zhang Hui | 1 |
Publication | Filing date | Title |
---|---|---|
WO2012071469A2 | Histone demethylase inhibitors and uses thereof for treatment o f cancer | |
WO2010124143A1 | Reprogramming of somatic cells with purified proteins | |
WO2010042800A1 | Methods of reprogramming somatic cells and methods of use for such cells | |
WO2009092042A1 | Reprogramming of differentiated progenitor or somatic cells using homologous recombination | |
WO2008151021A1 | Isolation and growth of stem cells from hemangiomas | |
US2008299077A1 | Isolation and growth of stem cells from hemangiomas | |
US2008182806A1 | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents | |
US2008241110A1 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) | |
CA2631312A1 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |